Brümmendorf, Tim H.
Gambacorti-Passerini, Carlo
Bushmakin, Andrew G.
Cappelleri, Joseph C.
Viqueira, Andrea
Reisman, Arlene
Isfort, Susanne
Mamolo, Carla
Funding for this research was provided by:
Universitätsklinikum RWTH Aachen
Article History
Received: 31 January 2020
Accepted: 30 March 2020
First Online: 19 April 2020
Compliance with ethical standards
: The study was conducted in accordance with the Declaration of Helsinki, the protocol was approved by the Institutional Review Board at each study center, and all patients provided written informed consent.
: Tim H. Brümmendorf reports consultancy within the past 2 years for Novartis, Pfizer, Ariad, Janssen, and Merck, research funding from Novartis and Pfizer, honoraria from Pfizer, and other relationships with Novartis. Carlo Gambacorti-Passerini reports consultancy within the past 2 years for Bristol-Myers Squibb, and research funding and honoraria from Pfizer. Andrew G. Bushmakin, Joseph C. Cappelleri, Andrea Viqueira, Arlene Reisman, and Carla Mamolo are employed by Pfizer and own stock in Pfizer. Susanne Isfort reports consultancy within the past 2 years for Novartis and Pfizer, and honoraria from Novartis, Pfizer, Bristol-Myers Squibb, and Ariad/Incyte.